Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.37 +2.2%	$1.34	$0.86 ▼ $3.78	$299.66M	0.31	3.32 million shs	1.76 million shs
EDIT Editas Medicine	$2.16 +9.6%	$1.58	$0.91 ▼ $6.05	$164.92M	2.1	2.58 million shs	2.81 million shs
FDMT 4D Molecular Therapeutics	$4.37 -0.5%	$3.49	$2.24 ▼ $28.93	$202.44M	2.84	828,883 shs	285,157 shs
NVAX Novavax	$7.03 +1.3%	$6.72	$5.01 ▼ $17.81	$1.14B	2.8	6.52 million shs	4.58 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-5.63%	+20.72%	-27.57%	-42.98%
EDIT Editas Medicine	0.00%	+3.14%	+30.46%	+39.72%	-61.07%
FDMT 4D Molecular Therapeutics	0.00%	+0.92%	+27.62%	+5.02%	-81.42%
NVAX Novavax	0.00%	-6.85%	+3.12%	-17.18%	-51.81%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	3.791 of 5 stars	4.5	3.0	0.0	2.5	3.3	0.6
EDIT Editas Medicine	4.2382 of 5 stars	3.1	2.0	4.2	2.8	2.5	1.3
FDMT 4D Molecular Therapeutics	2.557 of 5 stars	3.3	3.0	0.0	2.8	1.7	0.6
NVAX Novavax	3.883 of 5 stars	3.3	2.0	4.7	2.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	516.38% Upside
EDIT Editas Medicine	2.29	Hold	$5.36	148.32% Upside
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	576.33% Upside
NVAX Novavax	2.50	Moderate Buy	$19.20	173.12% Upside

Current Analyst Ratings Breakdown

Latest ALLO, NVAX, FDMT, and EDIT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/19/2025	NVAX Novavax	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/15/2025	ALLO Allogene Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/14/2025	ALLO Allogene Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $7.00
5/14/2025	ALLO Allogene Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$12.00 ➝ $9.00
5/14/2025	ALLO Allogene Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $4.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$22K	13,620.98	N/A	N/A	$3.04 per share	0.45
EDIT Editas Medicine	$35.84M	5.05	N/A	N/A	$4.27 per share	0.51
FDMT 4D Molecular Therapeutics	$23K	8,801.75	N/A	N/A	$7.20 per share	0.61
NVAX Novavax	$1.21B	0.94	N/A	N/A	($6.04) per share	-1.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$327.27M	-$1.23	N/A	N/A	N/A	N/A	-52.13%	-41.29%	8/6/2025 (Estimated)
EDIT Editas Medicine	-$153.22M	-$3.04	N/A	N/A	N/A	-340.96%	-80.13%	-50.99%	8/6/2025 (Estimated)
FDMT 4D Molecular Therapeutics	-$100.84M	-$3.18	N/A	N/A	N/A	N/A	-28.00%	-26.16%	8/14/2025 (Estimated)
NVAX Novavax	-$545.06M	$2.65	N/A	87.88	2.85	-32.18%	N/A	-17.05%	8/14/2025 (Estimated)

Latest ALLO, NVAX, FDMT, and EDIT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/12/2025	Q1 2025	EDIT Editas Medicine	-$0.51	-$0.43	+$0.08	-$0.92	$0.79 million	$4.66 million
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A
5/8/2025	Q1 2025	NVAX Novavax	$0.71	$2.93	+$2.22	$2.93	$204.08 million	$666.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.35	9.35
EDIT Editas Medicine	N/A	3.75	3.75
FDMT 4D Molecular Therapeutics	N/A	17.33	17.33
NVAX Novavax	N/A	0.93	0.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
EDIT Editas Medicine	71.90%
FDMT 4D Molecular Therapeutics	99.27%
NVAX Novavax	53.04%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
EDIT Editas Medicine	2.10%
FDMT 4D Molecular Therapeutics	9.60%
NVAX Novavax	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	158.72 million	Optionable
EDIT Editas Medicine	230	83.71 million	80.98 million	Optionable
FDMT 4D Molecular Therapeutics	120	46.33 million	42.85 million	Optionable
NVAX Novavax	1,990	161.97 million	158.58 million	Optionable

ALLO, NVAX, FDMT, and EDIT Headlines

Recent News About These Companies

Analysts Conflicted on These Healthcare Names: Novavax (NVAX) and Intuitive Surgical (ISRG)

June 14 at 3:02 AM | theglobeandmail.com

Novavax: New Vaccine, Same Old Story - Still A Sell

June 13 at 11:52 AM | seekingalpha.com

Novavax, Inc. (NASDAQ:NVAX) Shares Sold by SG Americas Securities LLC

June 13 at 4:21 AM | marketbeat.com

Novavax's COVID-Flu Combo Shot Shows Strong Immune Response

June 12, 2025 | zacks.com

Novavax's COVID-flu combo vaccine shows strong immune response in trial

June 12, 2025 | msn.com

Novavax preps late-stage trial as COVID-flu combo vaccine matches rivals

June 12, 2025 | thepharmaletter.com

Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

June 11, 2025 | seekingalpha.com

Novavax’s COVID-flu combo vaccine shows strong immune response

June 11, 2025 | msn.com

Tesla, Victoria’s Secret, Novavax rise premarket; Chewy, Gitlab fall

June 11, 2025 | investing.com

Novavax posts immune data to back COVID-flu combo shot and standalone flu shot

June 11, 2025 | msn.com

Novavax (NasdaqGS:NVAX) Announces Promising Results for New Vaccine Candidates

June 11, 2025 | finance.yahoo.com

Novavax’s Covid-Flu Combo, Standalone Flu Vaccines Demonstrate Robust Immune Response In Late-Stage Trial: Retail Says It’s ‘A Very Good Sign’

June 11, 2025 | msn.com

Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial

June 11, 2025 | benzinga.com

Novavax (NVAX) is a Top-Ranked Momentum Stock: Should You Buy?

June 11, 2025 | zacks.com

Novavax Stock (NVAX) Gets a Boost from ‘Robust Immune Responses’

June 11, 2025 | tipranks.com

Novavax Reports Promising Phase 3 Vaccine Trial Results

June 11, 2025 | tipranks.com

Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study

June 11, 2025 | reuters.com

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

June 11, 2025 | prnewswire.com

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

June 10, 2025 | barrons.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.16 Million Position in Novavax, Inc. (NASDAQ:NVAX)

June 7, 2025 | marketbeat.com

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

June 6, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
By Leo Miller | June 14, 2025
View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY
By Thomas Hughes | June 11, 2025
View Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY

ALLO, NVAX, FDMT, and EDIT Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.37 +0.03 (+2.24%)

Closing price 04:00 PM Eastern

Extended Trading

$1.36 -0.02 (-1.09%)

As of 07:51 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Editas Medicine NASDAQ:EDIT

$2.16 +0.19 (+9.64%)

Closing price 04:00 PM Eastern

Extended Trading

$2.15 -0.01 (-0.65%)

As of 07:50 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

4D Molecular Therapeutics NASDAQ:FDMT

$4.37 -0.02 (-0.46%)

Closing price 04:00 PM Eastern

Extended Trading

$4.50 +0.14 (+3.09%)

As of 07:27 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Novavax NASDAQ:NVAX

$7.03 +0.09 (+1.30%)

Closing price 04:00 PM Eastern

Extended Trading

$7.00 -0.03 (-0.43%)

As of 07:59 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time